Source comparison
Pulsatile Dosing Protocols vs Sustained-Release Formulations
The difference between CJC-1295 no DAC and CJC-1295 with DAC isn't just pharmacokinetic. It's a completely different dosing paradigm. CJC-1295 no DAC requires administration 1–3 times daily, typically timed around natural GH pulse windows: before bed (when end
This comparison does not assign a generated winner or score.
- The difference between CJC-1295 no DAC and CJC-1295 with DAC isn't just pharmacokinetic. It's a completely different dosing paradigm. CJC-1295 no DAC requires administration 1–3 times daily, typically timed around natural GH pulse windows: before bed (when endogenous GH secretion peaks during slow-wave sleep), post-workout (when exercise-induced GH pulses occur), or in a fasted state in the morning. Each injection produces a GH pulse that peaks within 30–60 minutes and returns to baseline within 2–3 hours. The DAC version is administered once or twice weekly because the Drug Affinity Complex binds to serum albumin, creating a sustained-release reservoir that maintains GHRH receptor activation for 6–8 days.
- This creates a fundamental trade-off. The DAC modification eliminates the need for frequent injections, which is why it's often marketed as more 'convenient.' What the marketing rarely mentions is the biological cost: sustained GHRH receptor activation suppresses your natural GH secretory capacity over time. Studies published in the Journal of Pediatric Endocrinology & Metabolism show that continuous GHRH exposure downregulates pituitary GHRH receptors by 40–60% within 14 days, reducing endogenous GH response even when exogenous GHRH is withdrawn. Recovery takes 4–8 weeks. That suppression doesn't occur with pulsatile dosing because receptor expression recovers fully between pulses.
- For research applications, this matters because the goal isn't just to elevate GH. It's to study how the body responds to augmented endogenous secretion without eliminating the signal your hypothalamus controls. CJC-1295 no DAC natural GH augmentation preserves that control. Dosing protocols typically range from 100–200 mcg per injection, administered subcutaneously. Timing matters more than dose: injections given 30 minutes before anticipated GH pulse windows (bedtime, post-resistance training) produce significantly greater peak GH elevation than random-timed administration. In our experience working with labs running multi-week GH secretagogue studies, the difference between a well-timed protocol and a poorly timed one often determines whether measurable IGF-1 changes occur at all. Precision matters. And precision starts with the peptide itself. Every batch we supply through our peptide collection undergoes mass spectrometry verification to confirm the exact 29-amino-acid sequence CJ